

Szeged, Department of Dermatology and Allergology, Szeged, Hungary; <sup>11</sup>Christie Hospital NHS Foundation Trust, Department of Plastic Surgery, Manchester, United Kingdom; <sup>12</sup>Klinikum Wels-Grieskirchen, Department of Dermatology, Wels, Austria; <sup>13</sup>Dermatologic Clinic University of Torino, Department of Medical Sciences, Torino, Italy; <sup>14</sup>Institute of Oncology University of Ljubljana, Department of Oncology, Ljubljana, Slovenia; <sup>15</sup>University of Rome La Sapienza, Dermatology, Rome, Italy; <sup>16</sup>Ruhr-Universität, Klinik für Dermatologie- Venerologie und Allergologie, Bochum, Germany; <sup>17</sup>Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Department of Soft Tissue/Bone Sarcoma and Melanoma, Warsaw, Poland; <sup>18</sup>San Martino Hospital, Department of Clinical Surgery, Genova, Italy; <sup>19</sup>Castle Hill Hospital, Department of Plastic Surgery, Castle Hill, United Kingdom; <sup>20</sup>Center for Experimental Drug and Gene Electrotransfer C\_EDGE-, Department of Clinical Oncology and Palliative Care- Zealand University Hospital, Roskilde, Denmark

**Background.** Electrochemotherapy is a treatment for tumours in the skin, both primary and metastatic. The international Network for sharing practices on Electrochemotherapy (InspECT) group gathers information on treatment outcomes in a common database with defined, outcome parameters in order to improve and guide the use of Electrochemotherapy (ECT). Over a period of 10 years we have investigated the effectiveness of ECT in cutaneous melanoma metastasis and identified factors which affect the outcome.

**Methods.** 20 treatment centers across Europe have treated and uploaded melanoma data to the InspECT database. Patients were given intratumoural or intravenous Bleomycin followed by the application of electric pulses to the tumour nodules, under local or general anaesthesia. Up to 7 tumor lesions were registered for each patient. Response rates were investigated in relation to tumour size, choice of electrode type, and route of bleomycin administration, as well as previous irradiation to the treated lesions.

**Results.** 246 patients with metastatic melanoma were identified from the database, 203 of which had follow-up data of 60 days or more. 161 of these patients (80 %) experienced an overall response (complete response + partial response = OR). 679 lesions were treated, with an overall response seen in 571 lesions (84 %), and a complete response seen in 453 lesions (67 %). In multivariate analysis, factors positively associated with overall response were coverage of deep margins, absence of visceral metastases, presence of lymphoedema, and treatment of non-irradiated areas. These factors significantly influenced treatment efficacy. Factors significant associated with a complete response to ECT treatment were: coverage of deep margins, previous irradiation of treated area, and tumour size (<3 cm). One-year overall survival in this cohort of patients was 67% (C.I. 95%: 57%-77%), whilst melanoma specific survival was 74% (C.I. 95%: 64%-84%). No serious adverse events were reported, and the treatment was in general very well tolerated.

**Conclusion.** ECT is a highly effective local treatment for cutaneous melanoma metastases, with no severe adverse effects. In the presence of certain clinical factors, ECT may be considered for local tumour control as an alternative to established local treatments, or as an adjunct to systemic treatments.

**Conflict of interest:** No conflict of interest.

## 65

### HIGH RESPONSE RATES AFTER NEOADJUVANT CYTOREDUCTIVE TREATMENT WITH BRAF/MEK INHIBITION OF PRIOR UNRESECTABLE REGIONALLY ADVANCED MELANOMA, REDUCTOR TRIAL

S. Blankenstein<sup>1</sup>, M. Rohaan<sup>2</sup>, M. Klop<sup>3</sup>, B. Van der Hiel<sup>4</sup>, B. Van de Wiel<sup>5</sup>, D. Peep<sup>6</sup>, J. Haanen<sup>2</sup>, A. van Akkooi<sup>1</sup>. <sup>1</sup>Netherlands Cancer Institute-Antoni van Leeuwenhoek, Surgical oncology, Amsterdam, Netherlands; <sup>2</sup>Netherlands Cancer Institute-Antoni van Leeuwenhoek, Medical oncology, Amsterdam, Netherlands; <sup>3</sup>Netherlands Cancer Institute-Antoni van Leeuwenhoek, Head and Neck Surgery and Oncology, Amsterdam, Netherlands; <sup>4</sup>Netherlands Cancer Institute-Antoni van Leeuwenhoek, Nuclear medicine, Amsterdam, Netherlands; <sup>5</sup>Netherlands Cancer Institute-Antoni van Leeuwenhoek, Pathology, Amsterdam, Netherlands; <sup>6</sup>Netherlands Cancer Institute-Antoni van Leeuwenhoek, Molecular Oncology and Immunology, Amsterdam, Netherlands

**Background:** The aim of this trial is to evaluate the potency of short-term neoadjuvant cytoreductive therapy with dabrafenib and trametinib (BRAF and MEK inhibitor respectively) to allow radical surgical resection in patients with unresectable BRAF-mutated, locally advanced stage III or oligometastatic stage IV melanoma.

**Patients and methods:** A total of 25 patients with BRAF-mutated, unresectable locally advanced stage III or oligometastatic stage IV ( $\leq 3$  metastases) melanoma will be treated with dabrafenib and trametinib for 8 weeks. Response evaluation by positron emission tomography/computed tomography (PET/CT) will occur at 2 and 8 weeks. If sufficient downsizing occurs, surgical resection will be performed. Biopsies for translational research will be taken at baseline and 2 weeks. The dissection specimen will be stored at 8 weeks.

**Results:** Currently 17 patients have been included. Of these, 2 patients showed progressive disease upon treatment and did not proceed to surgery. In 14/15 (93%) patients resection was possible after neoadjuvant treatment, of which 13 (93%) were R0 resections. Median follow-up time is 22 months with a median recurrence free survival of 9 months in patients undergoing surgery. The 1-year overall survival (OS) was 88% and 2-year OS 59%. Median OS was not reached. Metabolic response rates on PET/CT after 8 weeks were: 4 (24%) CR, 11 (65%) PR, 0 (0%) SD, 2 (12%) PD. Pathologic response rates differed: 6 (35%) CR, 5 (29%) PR, 3 (19%) SD, 0 (0%) PD and in 3 patients (18%) no pathologic response was measured, since no resection was performed. In 6 patients a more favorable outcome was seen in the pathologic response rates, compared to metabolic response rates. Most patients (82%) experienced any toxicity, of which the majority (64%) was grade 1 and the most common reported toxicity was fever. Grade 3 toxicity occurred in 2 patients (12%).

**Conclusions:** Neoadjuvant dabrafenib and trametinib shows to be a potent cytoreductive treatment, allowing radical resection of metastases in 13/17 (76%) patients with prior unresectable locally advanced melanoma. Differences were seen between metabolic response rate on PET/CT and pathologic response rate, where in most patients pathologic response was more favorable than metabolic response. Patients with no recurrent disease remained disease-free for a prolonged period of time. If recurrent disease did occur, this was usually seen within months after surgery. This may present an opportunity for further tailored adjuvant therapy, for which we would propose continuation of dabrafenib and trametinib, or switch to immunotherapy in case of insufficient response.

**Conflict of interest Other Substantive Relationships:** Daniel Peep: research support from BMS, John Haanen: Through JH, NKI has received compensation for advisory roles from BMS, Merck, Roche, NEON therapeutics, Pfizer and Ipsen and NKI has received grants from BMS, Merck, Novartis and NEON therapeutics. Alexander van Akkooi: consulting or advisory role for Amgen, Novartis, MSD Oncology, Merck. Research funding from Amgen and Novartis. Travel, accommodations and expenses from Amgen, Roche and Novartis.

## 66

### LONG-TERM NORMOTHERMIC INTRAPERITONEAL AND SYSTEMIC CHEMOTHERAPY FOR GASTRIC CANCER WITH PERITONEAL METASTASIS: RESULTS FROM CLINICAL TRIALS OVER A DECADE IN JAPAN

H. Ishigami<sup>1</sup>, T. Omori<sup>2</sup>, R. Fukushima<sup>3</sup>, M. Imano<sup>4</sup>, H. Miwa<sup>5</sup>, D. Kobayashi<sup>6</sup>, H. Yabusaki<sup>7</sup>, K. Misawa<sup>8</sup>, T. Arigami<sup>9</sup>, K. Amagai<sup>10</sup>, Y. Hirono<sup>11</sup>, A. Hidemura<sup>12</sup>, K. Imamura<sup>13</sup>, K. Ogata<sup>14</sup>, T. Kusumoto<sup>15</sup>, S. Ueda<sup>16</sup>, T. Matsumura<sup>17</sup>, S. Yoshida<sup>18</sup>, H. Yamaguchi<sup>19</sup>, J. Kitayama<sup>20</sup>. On behalf of Japan Intraperitoneal Chemotherapy Study Group (JIPG)<sup>1</sup> The University of Tokyo, Department of Chemotherapy, Tokyo, Japan; <sup>2</sup>Osaka International Cancer Institute, Department of Gastroenterological Surgery, Osaka, Japan; <sup>3</sup>Teikyo University, Department of Surgery, Tokyo, Japan; <sup>4</sup>Kindai University School of Medicine, Department of Surgery, Osaka-Sayama, Japan; <sup>5</sup>Hyogo College of Medicine, Department of Gastroenterology, Nishinomiya, Japan; <sup>6</sup>Nagoya University Graduate School of Medicine, Department of Gastroenterological Surgery, Nagoya, Japan; <sup>7</sup>Niigata Cancer Center Hospital, Department of Gastroenterological Surgery, Niigata, Japan; <sup>8</sup>Aichi Cancer Center Hospital, Department of Gastroenterological Surgery, Nagoya, Japan; <sup>9</sup>Kagoshima University Graduate School of Medical and Dental Sciences, Department of Oncobiological Surgery, Kagoshima, Japan; <sup>10</sup>Ibaraki Prefectural Central Hospital

and Cancer Center, Division of Gastroenterology, Kasama, Japan; <sup>11</sup> University of Fukui, Department of Gastroenterological Surgery, Fukui, Japan; <sup>12</sup> Kanto Rosai Hospital, Department of Surgery, Kawasaki, Japan; <sup>13</sup> Tokyo Metropolitan Tama Medical Center, Department of Surgery, Fuchu, Japan; <sup>14</sup> Gunma University Hospital, Integrative Center of General Surgery-Division of Gastroenterological Surgery, Maebashi, Japan; <sup>15</sup> National Kyushu Medical Center, Department of Gastroenterological Surgery and Clinical Research Institute Cancer Research Division, Fukuoka, Japan; <sup>16</sup> Kitano Hospital- Tazuke-Kofukai Medical Research Institute, Department of Gastroenterological Surgery and Oncology, Osaka, Japan; <sup>17</sup> Aichi Medical University, Department of Gastroenterological Surgery, Nagakute, Japan; <sup>18</sup> The University of Tokyo Graduate School of Medicine, Department of Gastroenterology, Tokyo, Japan; <sup>19</sup> Jichi Medical University, Department of Clinical Oncology, Shimotsuke, Japan; <sup>20</sup> Jichi Medical University, Support Center for Clinical Investigation, Shimotsuke, Japan

**Background:** Intraperitoneal (ip) chemotherapy is a promising treatment option for peritoneal malignancy. However, even with cytoreductive surgery and hyperthermia, bolus ip chemotherapy for 30–60 minutes may not be sufficiently effective for gastric cancer with peritoneal metastasis. We have developed a new multidisciplinary treatment with long-term normothermic ip and systemic chemotherapy, using paclitaxel (PTX) or docetaxel (DOC) for ip administration via an ip port, combined with gastrectomy after response to chemotherapy. These drugs have pharmacokinetic properties that allow high local concentration, and rarely cause adhesions in the peritoneal cavity. Here we report the results of 10 clinical trials completed between 2006 and 2018 and a retrospective study of surgery after response to chemotherapy.

**Material and methods:** We performed phase I clinical trials of five combination chemotherapy regimens: S-1/PTX plus ip PTX, S-1/oxaliplatin plus ip PTX, S-1/cisplatin plus ip PTX, capecitabine/cisplatin plus ip DOC, and FOLFOX plus ip PTX. We completed single- or multicenter phase II clinical trials of the first three regimens and a multicenter phase III PHOENIX-GC trial comparing S-1/PTX plus ip PTX with standard systemic chemotherapy. Additionally, we retrospectively evaluated the safety and efficacy of gastrectomy in three multicenter phase II and III trials.

**Results:** In phase I trials, recommended doses of weekly ip PTX and ip DOC were determined to be 20–40 mg/m<sup>2</sup> and 10 mg/m<sup>2</sup>, respectively, with systemic dose-limiting toxicities. In phase II trials, the median durations of protocol treatment were 18–33 weeks. The 1-year overall survival rates were 72%–78%, and the negative conversion rates on peritoneal cytology were 68%–86%. The common grade 3/4 adverse events were leukopenia (8%–28%), neutropenia (21%–50%), anemia (9%–29%), and anorexia (0%–25%). PHOENIX-GC trial narrowly failed to show statistical superiority of S-1/PTX plus ip PTX over S-1 plus cisplatin ( $p=0.080$ ; hazard ratio [HR] 0.72, 95% confidence interval [CI] 0.49–1.04). However, the exploratory analysis adjusting for the baseline imbalance in the amount of ascites between the arms suggested clinical benefits (HR 0.59, 95% CI 0.39–0.87). Out of 222 patients treated with ip chemotherapy in three multicenter trials, 93 patients (42%) underwent gastrectomy after disappearance or marked shrinkage of peritoneal metastasis. The median survival times of patients with and without surgery were 26.3 months (95% CI 21.3–34.2 months) and 12.3 months (95% CI 11.3–13.1 months), respectively. Postoperative complications of Clavien-Dindo grade II–IVa occurred in 10 patients, with no treatment-related deaths.

**Conclusions:** Multidisciplinary treatment with long-term ip and systemic chemotherapy combined with gastrectomy is safe and effective for gastric cancer patients with peritoneal metastasis.

**Conflict of interest Other Substantive Relationships:** Drugs were provided by Nippon Kayaku Co.,Ltd., Sawai Pharmaceutical Co.,Ltd., Yakult Honsha Co.,Ltd., and Kyowa HAKKO Kirin Co.,Ltd. in some of the clinical trials.

## 67

### ACTIVE SURVEILLANCE VERSUS SURGERY IN CLINICALLY COMPLETE RESPONDERS AFTER NEOADJUVANT CHEMORADIOTHERAPY FOR ESOPHAGEAL CANCER: A PROPENSITY-MATCHED STUDY

B. Van Der Wilk<sup>1</sup>, L.K.A. Neijenhuis<sup>1</sup>, B.J. Noordman<sup>1</sup>, G.A.P. Nieuwenhuijzen<sup>2</sup>, M.N. Sosef<sup>3</sup>, M.I. van Berge Henegouwen<sup>4</sup>, S.M. Lagarde<sup>1</sup>, B.P.L. Wijnhoven<sup>1</sup>, A. van der Gaast<sup>5</sup>, J.J.B. van

Lanschot<sup>1</sup>, <sup>1</sup> Erasmus MC, Surgery, Rotterdam, Netherlands; <sup>2</sup> Catharina Cancer Center, Surgery, Eindhoven, Netherlands; <sup>3</sup> Zuyderland MC, Surgery, Heerlen, Netherlands; <sup>4</sup> Academic Medical Center, Surgery, Amsterdam, Netherlands; <sup>5</sup> Erasmus MC, Medical Oncology, Rotterdam, Netherlands

**Background.** Nearly one third of esophageal cancer patients show a pathologically complete response in their resection specimens after neoadjuvant chemoradiotherapy (nCRT) according to CROSS regimen. This raises questions whether all patients benefit from surgery or if active surveillance can be applied to patients with a clinically complete response (cCR) after nCRT. This retrospective-multicenter propensity matched study compared outcomes of patients with a cCR after nCRT undergoing active surveillance or standard surgery.

**Material and Methods.** Patients that refused surgery after nCRT between 2012–2017 from 4 hospitals were included. For the standard surgery group, patients from the preSANO trial were enrolled. A cCR was defined as endoscopies with multiple (bite-on-bite) biopsies, EUS-FNA and PET-CT showing no residual disease 6 and 12 weeks after completion of nCRT.

Optimal propensity-score matching generated a matched cohort (1:2) matched for age, comorbidities, cT, cN, histology of the tumor and biopsy type. For comparison of severity of complications according to Clavien-Dindo (CD) classification, a separate optimal propensity-score matching cohort was generated (1:2) for all patients in the active surveillance group that underwent surgery.

Primary outcome was overall survival, secondary outcomes were rate of radically resected tumors, distant dissemination rate and rate of post-operative complications according to the CD-classification.

**Results.** 75 patients were identified of whom 50 patients underwent standard surgery and 25 patients underwent active surveillance. 13 of 25 patients in the active surveillance group underwent surgery for locoregional recurrent disease. Median follow-up was 23.7 months for the standard surgery group and 18.8 months for the active surveillance group. There was no statistically significant difference between the groups in overall survival (HR=0.48, 95%CI. 0.10–2.2,P=0.96). In both groups, all tumors were radically resected. There were no statistically significant differences in distant dissemination rate between the active surveillance and standard surgery group (16.0% versus 22.0%,P=0.76) or in severity of complications (CD≥3;46.2% versus 23.1%,P=0.16).

**Conclusion.** There was no statistically significant difference in overall survival, distant dissemination rate and severity of complications between patients undergoing standard surgery or active surveillance after nCRT. However, since sample sizes were small, especially for the severity of complications, these results should be interpreted with caution.

**Conflict of interest:** No conflict of interest.

## 68

### IMPLEMENTING INTEGRATED QUALITY ASSURANCE (SURCARE) FOR EORTC-JCOG 1527 / ESO 02: DIFFUSION-WEIGHTED MAGNETIC RESONANCE IMAGING (DW-MRI) ASSESSMENT OF LIVER METASTASIS TO IMPROVE SURGICAL PLANNING (DREAM)

K. Kataoka<sup>2</sup>, C.I. Caballero<sup>1</sup>, T. Suto<sup>3</sup>, O. Masayuki<sup>4</sup>, C.K. Hyunseon<sup>5</sup>, R. Troisi<sup>6</sup>, T. Yasumasa<sup>7</sup>, H. Uetake<sup>8</sup>, T. Nobuhiro<sup>9</sup>, Y. Kazuhiro<sup>10</sup>, O. Hitoshi<sup>11</sup>, Y. Kishi<sup>12</sup>, A. Shiomi<sup>13</sup>, M. Ducreux<sup>14</sup>, B. Bonhomme<sup>15</sup>, L. Collette<sup>16</sup>, L. Rubbia-Brandt<sup>17</sup>, G. Brown<sup>18</sup>, M. Shiozawa<sup>19</sup>, S. Evrard<sup>20</sup>. On behalf of EORTC GITCG and JCOG investigators and ESO Clinical Research Committee<sup>1</sup> EORTC, Medical, Brussel, Belgium; <sup>2</sup> Hyogo College of Medicine, Colorectal Cancer Surgery, Hyogo, Japan; <sup>3</sup> Yamagata Prefectural Central Hospital, Surgery, Yamagata, Japan; <sup>4</sup> Osaka Medical Center for Cancer and Cardiovascular Diseases, Surgery, Osaka, Japan; <sup>5</sup> The University of Texas MD Anderson Cancer Center, Radiology, Houston, USA; <sup>6</sup> Universitair Ziekenhuis Gent, Hepatobiliary Surgery, Gent, Belgium; <sup>7</sup> Niigata Prefectural Cancer Center Hospital, Surgery, Niigata, Japan; <sup>8</sup> Tokyo Medical and Dental University, Surgery, Tokyo, Japan; <sup>9</sup> Chiba Cancer Center, Surgery, Chiba, Japan; <sup>10</sup> Gifu University Hospital, Surgery, Gifu, Japan; <sup>11</sup> Gunma Cancer Center, Surgery, Gunma, Japan; <sup>12</sup> National Cancer Center, Surgery, Tokyo, Japan; <sup>13</sup> Shizuoka Cancer Center, Surgery, Shizuoka, Japan; <sup>14</sup> Gustave Roussy, Oncology, Villejuif, France; <sup>15</sup> Institut Bergonie, Pathology, Bordeaux, France; <sup>16</sup> EORTC, Statistics, Brussel, Belgium; <sup>17</sup> Hôpitaux Universitaires de Genève, Pathology, Geneva, Switzerland; <sup>18</sup> Royal Marsden NHS Foundation, Radiology, Sutton, United Kingdom;